Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
Berardi G, Cucchetti A, Sposito C, Ratti F, Nebbia M, D’Souza D, Pascual F, Dogeas E, Tohme S, Vitale A, D’Amico F, Alessandris R, Panetta V, Simonelli I, Colasanti M, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimitti G, Famularo S, Ivanics T, Donando F, Hoffman D, Onkendi E, Essaji Y, Giuliani T, Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Sapisochin G, Torzilli G, Corvera C, Alseidi A, Helton S, Troisi R, Simo K, Conrad C, Cescon M, Cleary S, Kwon D, Ferrero A, Ettorre G, Cillo U, Geller D, Cherqui D, Serrano P, Ferrone C, Aldrighetti L, Kingham T, Mazzaferro V. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome. JHEP Reports 2024, 6: 101075. PMID: 38961853, PMCID: PMC11220535, DOI: 10.1016/j.jhepr.2024.101075.Peer-Reviewed Original ResearchLong-term outcomes of liver resectionRecurrence-free survivalTime of recurrenceCancer-specific survivalTumor-related factorsDevelopment of hepatocellular carcinomaHepatocellular carcinomaMetabolic syndromeLong-term survivalRisk factorsOverall survivalImpact survivalResection of hepatocellular carcinomaOutcomes of liver resectionCurative intent approachPost-recurrence survivalPredictors of recurrenceHazard of recurrenceTreatment of recurrenceRisk of recurrenceTumor-related deathLong-term outcomesDesigning future trialsAssociated with deathMedian OSEx situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy
Nieddu E, Billato I, Peluso C, Furlanetto A, Lazzari S, D'Amico F, Cillo U, Gringeri E. Ex situ liver resection for intrahepatic cholangiocarcinoma: survival analysis and comparison to systemic chemotherapy. Digestive And Liver Disease 2024, 56: s42. DOI: 10.1016/j.dld.2024.01.067.Peer-Reviewed Original ResearchProgression-free survivalCA19-9 levelsEx situ liver resectionOverall survivalIntrahepatic cholangiocarcinomaEx situ surgeryStage of diseasePerformance statusSystemic chemotherapySurgical resectionLiver resectionLiver functionHigh-volume hepatobiliary centersLower stage of diseaseMedian progression-free survivalTreated with surgical resectionEvaluate long-term outcomesSurvival analysisEx situ resectionNon-parametric log-rank testTreated with chemotherapyLog-rank testLiver function testsCox regression analysisLong-term outcomesLiver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis
Romano P, Busti M, Billato I, D’Amico F, Marchegiani G, Pelizzaro F, Vitale A, Cillo U. Liver resection versus radiofrequency ablation or trans-arterial chemoembolization for early-stage (BCLC A) oligo-nodular hepatocellular carcinoma: meta-analysis. BJS Open 2024, 8: zrad158. PMID: 38323881, PMCID: PMC10848305, DOI: 10.1093/bjsopen/zrad158.Peer-Reviewed Original ResearchConceptsBarcelona Clinic Liver CancerTrans-arterial chemoembolizationDisease-free survivalBarcelona Clinic Liver Cancer-A patientsBenefits of LRLiver resectionRadiofrequency ablationHepatocellular carcinomaOS benefitOverall survivalA patientsBarcelona Clinic Liver Cancer ABarcelona Clinic Liver Cancer stageDisease-free survival benefitRisk ratioOutcomes of LRMeta-analysisComparative cohort studyCase-control studyChina Biological Medicine DatabaseHCC patientsCohort studyPrimary outcomeNewcastle-OttawaQuality of studies